Background: While preprocedural statin treatment for acute coronary syndrome (ACS) is widely regarded as beneficial, there has been no prospective randomized multicenter trial of patients with non-ST elevation ACS in the Japanese population to examine the efficacy of preprocedural aggressive statin use. The aim of this study was to confirm this effect by prospective randomized multicenter design. Methods: Fifty patients who presented with non-ST elevation ACS were enrolled, and randomly assigned to aggressive statin administration before percutaneous coronary intervention (PCI). Troponin-T (TnT), creatine phosphokinase (CK), CK-myocardial band (CK-MB), high-sense Creactive protein (hs-CRP), and brain natriuretic peptide (BNP) were measured at baseline and/ or after procedure. Results: Three days after PCI, the statin group had significantly less CK elevation compared with the nonstatin group (84±17 IU/l versus 180±68 IU/l, respectively, p ¼ 0.02). CK-MB elevation also tended to be lower in the statin group than in the nonstatin group (3.2±1.9 versus. 7.0±3.0, respectively, p ¼ 0.07), as was BNP level (3.2±1.9 versus 7.0±3.0 pg/ml, respectively, p ¼ 0.07). The change of serum LDL cholesterol was significantly correlated with CK (p ¼ 0.01) and TnT (p ¼ 0.02) at 1 day after PCI. Conclusions: Aggressive statin usage before PCI to Japanese patients with non-ST elevation ACS appears to reduce myocardial damage after procedure. The degree of serum lipid level reduction may reflect the vulnerability of atheromatous plaques that could cause cardiac damage after PCI.
Introduction
In various randomized control studies, preprocedural 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statin) treatment for acute coronary syndrome (ACS) has been demonstrated to be beneficial in preventing acute cardiac events [de Lemos et al. 2004; Schwartz et al. 2001] , and may lead to better long-term outcomes. This study, designed as a prospective multicenter randomized trial, investigated the effects of preprocedural aggressive statin therapy to Japanese patients with non-ST elevation ACS.
The issue of racial difference in drug metabolism between Asians and Caucasians has been raised regarding satin usage, as Asian patients frequently have heightened responses to therapeutic drugs [Liao, 2007] . Statin usage in Japan has been restricted by the Ministry of Welfare for Toshiyuki Asahara Division of Cardiology, Tokyo Rosai Hospital, Tokyo, Japan example, the maximum permitted dosage of atorvastatin is 20 mg/day orally, except for patients with familial hypercholesterolemia. Statin treatment has been shown to reduce ischemic cardiovascular events by 2530% and to reduce low-density lipoprotein (LDL) cholesterol level by 2535% [The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 1998; Sacks et al. 1996; Scandinavian Simvastatin Survival Study Group, 1994] . Some of the beneficial effects of statins may be due to its pleiotropic effects on anti-inflammation [Jialal et al. 2001; Kluft et al. 1999; Ridker et al. 1999 Ridker et al. , 1998 Strandberg et al. 1999] , antithrombosis [Lacoste et al. 1995] , and vasculature [Dupuis et al. 1999] . ACS is considered to be a predictor for early recurrent cardiovascular events [The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 1999] . Therefore, we investigated the effect of preprocedural aggressive statin therapy to non-ST elevation ACS in the Japanese population.
Methods

Patients population and study design
This was a randomized prospective multicenter designed study, conducted at five centers in and around Tokyo, Japan. Inclusion criteria were non-ST elevation ACS on admission with typical symptoms and electrocardiogram changes. Exclusion criteria were ST elevation myocardial infarction, and rise of serum creatine phosphokinase (CK) level ! three times upper limit of normal on admission. Moreover, the following cases were excluded: left bundle-branch block or paced ventricular rhythm, severe congestive heart failure, cardiogenic shock, severe anemia, renal failure requiring dialysis and hepatic dysfunction. Patients who received cholesterol-lowering drugs before admission were not excluded, but administration of those drugs was suspended after randomization.
From March 2003 to August 2004, 50 patients (average age 65±14, 33 males) presented with non-ST elevation ACS underwent urgent percutaneous coronary intervention (PCI). Patients were randomized to an aggressive statin therapy group (atorvastatin 20 mg/day) or without statin (no statin administration before PCI) regardless of their previous statin treatment. Twenty-one patients were randomized to nonstatin and 16 patients received atorvastatin (20 mg/day).
According to our standard protocol, all patients received aspirin 81 mg/day or more before PCI, and ticlopidine 200 mg/day or cilostazol 200 mg/day for at least 2 weeks after stent placement. All patients received 100 IU/kg bolus of intravenous heparin before PCI, and activated clotting time was maintained at >250 s during the procedure.
PCI was performed in a standard manner, but the operators were blinded about the treatment group to eliminate any sources of bias. Angiographic success was defined by the final result of <50% residual stenosis by optical estimation. Stent implantation was performed according to current clinical practice, and limited to bare metal stents.
Troponin-T (TnT), CK and CK-myocardial band (CK-MB) were measured before and at 1, 2 and 3 days after the procedure. High-sense C-reactive protein (hs-CRP) was measured before PCI and 1 and 3 days after PCI. Brain natriuretic peptide (BNP) was measured at 3 days after the procedure. Total cholesterol, low-density lipoprotein cholesterol (LDL cholesterol), high-density lipoprotein cholesterol (HDL cholesterol), and triglyceride were measured before and 2 weeks after procedure. Informed consent was obtained from each patient.
Endpoints
The primary endpoint in this study was measurement of myocardial injury markers (CK, CK-MB, TnT), and inflammation marker (hs-CRP) in both groups. The secondary endpoint was correlation of serum lipid changes such as total cholesterol, LDL cholesterol, triglyceride and HDL-C, with cardiac markers.
Statistical analysis
Sample size calculation was performed using the Bland-Altman nomogram in terms of detecting a difference in the CK elevation after PCI between two groups with an assumed standard deviation of 40 IU/l and standardized difference of 1.0 (a power of 80% and a two-sided alpha level of 0.05), given the enrollment of approximately 30 patients. Other statistical analyses were performed using commercial software (Statview TM , Version 5.0, SAS Institute Inc., Cary, NC, USA). All data were analyzed as mean±1 standard deviation. Categorical variables were compared by 2 test. Unpaired Student's t-test was performed to compare continuous variables between two groups. Linear regression analyses were performed for assessing between continuous variables. A probability value of <0.05 was considered statistically significant.
Results
Fifty patients were enrolled in this study and randomized to the aggressive statin treatment group and nonstatin treatment group (Figure 1 ). Urgent coronary angiography was performed in all patients. Forty patients had significant organic stenosis, while 10 did not. Patients without significant organic stenosis underwent an acetylcholine provocation test to diagnose vasospasm, which could explain their symptoms and electrocardiogram changes. Three patients with vasospastic angina were diagnosed, and the remaining seven patients were excluded from this trial, because they did not have ischemic coronary artery disease. Within the 40 patients with significant organic stenosis, two patients had severe disease and underwent coronary artery bypass grafting. There was one patient who experienced systemic eruption after PCI, thought to be caused by medication, and this patient was excluded from data analysis. In all, data of 37 patients were analyzed for efficacy of aggressive statin treatment.
Baseline characteristics
Clinical and procedural variables for both aggressive atorvastatin and nonstatin groups are shown in Table 1 and Table 2 , respectively. Both groups were similar with regard to age, sex and cardiovascular risk factors. Frequency of smoking was higher in aggressive statin group than that in the nonstatin group (69% versus 43%, respectively, p ¼ 0.09), but did not reach statistical significance. Left ventricular ejection function, and body mass index were similar in both groups. There was no difference in concomitant medical treatment such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Use of b-blockers was less frequent in atorvastatin group, but was not significantly different from that in nonstatin group. Furthermore, there was no difference in statin use before admission in both groups (35.7% versus 27.6%, respectively, p ¼ 0.34). Procedural characteristics such as location of the stenosis were similar in both groups, and a balloon was used in most of the cases in both groups. Usage of stents was less frequent in the atorvastatin group, but this was not significant. Cutting balloon and directional coronary atherectomy were used more often in the nonstatin group, but neither device reached significant difference. In terms of rotational atherectomy, the usage in the atorvastatin group tended to be more frequent than in the nonstatin group (13% versus 0%, respectively, p ¼ 0.06). The distal protection device and aspiration catheter usage were not different in both groups. Stent use, total stent length, stent diameter and maximum pressure in inflation were similar in both groups. Procedural success was achieved in all patients. There were no complications or adverse events during the procedure and during statin administration for 2 weeks. All patients included in data analysis completed the 2 weektreatment period with or without atorvastatin.
Markers of myocardial damage
Pre-PCI baseline measurements of markers of myocardial injury such as CK, CK-MB TnT and hs-CRP as an inflammation marker were similar in both groups (Table 3) . There was no difference in measurements of myocardial markers in the two groups at 1 day and 2 days after treatment. However, CK in the aggressive statin group was significantly lower than that in the nonstatin group at 3 days after procedure (84±17 versus 180±68 IU/l, respectively, p ¼ 0.02). CK-MB fraction was lower in the atorvastatin group than in the nonstatin group, but did not reach statistical significance (3±4 versus 7±3 IU/l, respectively, p ¼ 0.07). There were no significance between the two groups with regard to levels of hs-CRP and TnT at 3 days after procedure, although both exhibited a similar trend as CK and CK-MB measurements. BNP level at 3 days after procedure tended to be lower in the aggressive statin group than in the nonstatin group (3.2±1.9 versus 7.0±3.0 pg/ml, respectively, p ¼ 0.07). BNP level at 3 days after PCI tended to positively correlate with baseline serum LDL cholesterol (95% confidence interval; CI, À0.66 to 3.02, p ¼ 0.08).
There was no difference in statin use before admission in both groups (35.7% versus 27.6%, respectively, p ¼ 0.34). In addition, after excluding those patients who had already taken statin before admission, the results of myocardial markers at 1 day and 2 days were also similar in the two groups. However, CK in the aggressive statin group, even after excluding patients on statin before admission, was significantly lower than that in the nonstatin group at 3 days after procedure (88±16 versus 180±68 IU/l, respectively, p ¼ 0.04). Either CK-MB fraction was lower in the atorvastatin group than in the nonstatin group, but did not reach statistical significance (3±2 versus 7±3 IU/l, respectively, p ¼ 0.09).
Serum lipid levels
There was no difference in lipid levels before treatment between the atorvastatin and nonstatin groups. Total cholesterol level before PCI was slightly lower in the nonstatin group (215.5±35.4 versus 199.5±52.3 mg/dl, p ¼ 0.30). Total cholesterol level after treatment was lower in the atorvastatin group (168.5±45.1 versus 193.0±48.9 mg/dl, p ¼ 0.14) than the nonstatin group, but this did not reach statistical significance. Therapeutic Advances in Cardiovascular Disease 3 (5)
There was a significant decrease in total cholesterol levels between baseline and 2 weeks after PCI (À49.7±35.8 versus À8.7±29.1 mg/dl, p ¼ 0.0006). In addition, there was a significant decrease in triglyceride levels between the two groups (À48.2±76.5 versus À5.1±39.2 mg/dl, p ¼ 0.04). While there was no significance of HDL cholesterol variation between two groups, HDL levels 2 weeks after treatment tended to be higher in the atorvastatin group (53.2±5.5 versus 47.5±10.1 mg/dl, p ¼ 0.08). There was a significant decrease in LDL cholesterol between the two groups (À47.5±32.7 versus À13.3±27.6 mg/dl, respectively, p ¼ 0.005). 
Relationship between lipid level and myocardial markers
We analyzed the relationship between variations in the cholesterol levels and biochemical markers of myocardial damage. Linear regression analysis demonstrated that LDL reduction was positively correlated with CK values at 1 day after procedure, shown in Figure 2 (95% CI; 0.04 to 0.28, p ¼ 0.01). The same pattern was seen in TnT levels at 1 day after procedure (Figure 3) . Reduction in LDL cholesterol was associated with higher measured levels of TnT (95% CI; 20.9 to 168.4, p ¼ 0.02). There was a similar tendency with CK-MB (p ¼ 0.09), but there was no significant correlation with LDL reduction.
In addition, there were significant correlations between HDL cholesterol and some myocardial markers. Baseline HDL cholesterol level had significant inverse correlation with hs-CRP at 1 day after PCI (95% CI; À62.3 to À12.2, p ¼ 0.007). Furthermore, CK value 1 day after procedure demonstrated significant positive correlation with the difference (post-pre PCI) of HDL cholesterol (95% CI; 0.001 to 0.051, p ¼ 0.04), and CK-MB at 1 day after treatment was correlated with the difference of HDL cholesterol (95% CI; 0.01 to 0.43, p ¼ 0.04). There was no significant correlation found between the change of triglyceride and myocardial markers, though there was a significant positive correlation between CK at 3 days after procedure and 2 weeks after treatment triglyceride value (95% CI; 0.11 to 1.00, p ¼ 0.02). Moreover, TnTat 3 days after treatment tended to have a correlation with post treatment triglyceride value (95% CI; À4.664 to 118.302, p ¼ 0.07).
Discussion
This is the first randomized trial with prospective multicenter design to study the effect of aggressive preprocedural statin treatment on Japanese patients presenting with non-ST elevation ACS.
Although we intended to administer 80 mg of atorvastatin, in accordance with comparable randomized trials abroad, there was restriction to limit the dosage of atorvastatin in our Japanese population. There are several clinical observational studies that demonstrate favorable results from preprocedural statin treatment, reducing myocardial injuries after PCI [Chan et al. 2003 [Chan et al. , 2002 Hermann et al. 2002] . Prior retrospective nonrandomized trials included a large number of patients using a variety of statin with various doses. In the present study, we used a fixed dose of 20 mg of atorvastatin for a short duration of 2 weeks after PCI, and our data revealed significant changes in the lipid profiles of patients in the atorvastatin group. Aggressive statin usage prior to PCI reduced the damage of myocardial markers 3 days after treatment, such as decreased CK elevation in the atorvastatin group compared with the nonstatin group. There was a trend of lower, CK-MB in the atorvastatin group, and a similar trend was seen with TnT and hsCRP levels. This did not reach statistical significance, presumably because of the small number of patients in the study. BNP level at 3 days after procedure showed the same favorable tendency, and reduction in elevation of serum BNP level has been suggested to provide a better longterm survival rate [Omland et al. 2002] .
Baseline lipid profile contributes to raising plaque volume, and results in elevated serum inflammation markers such as hs-CRP and BNP after PCI, and may negatively influence long-term outcomes. Our data suggests that triglyceride value at 2 weeks after procedure may have influenced elevation of myocardial markers post-PCI, suggesting that comprehensive lipid management is important in ACS.
With regard to patient safety issues, only one patient had a systemic eruption after PCI and was excluded from this study. As there were other medications administered to this patient at the same time such as ticlopidine and antibiotics, we could not determine that atorvastatin was solely responsible for this event. There were no other adverse effects from statin use such as myositis or myalgia that necessitated patients to quit their participation in this study.
The extent of total cholesterol and LDL cholesterol reduction within the aggressive statin group were greater than those in the nonstatin group. Greater reduction of LDL cholesterol significantly correlated with CK elevation and TnT elevation 1 day after procedure; that is, the greater the reduction of LDL, higher CK and TnT levels. This suggests that atorvastatin effectively removed the redundant serum cholesterol that causes myocardial injury and raise myocardial markers. Similar results were observed in the difference of HDL cholesterol (HDL posttreatment value and pretreatment value). There were significant positive correlations between observed difference of HDL cholesterol and CK, or CK-MB. Patients who had more room to improve their HDL cholesterol levels on atorvastatin may be interpreted as having a higher degree of dyslipidemia, leading to more significant CK/ CK-MB elevations after PCI. Our data support the results from a subanalysis of the MIRACLE study that focused on the influence of HDL cholesterol levels on shortterm prognosis after ACS [Olsson et al. 2005 ]. This subanalysis of the MIRACLE study demonstrated that HDL cholesterol measured in the initial stage of ACS predicted the risk of recurrent cardiovascular events over the ensuing 16 weeks. We did not follow the clinical events among the patients in our study, yet our data, which suggested the significant inverse correlation between baseline HDL cholesterol level and hs-CRP at 1 day after PCI, might have revealed the significance of the HDL cholesterol that could predict the cardiovascular events.
One study demonstrated that there was no correlation between the reduction of LDL cholesterol and subsequent change in natural-log-transformed hsCRP to the patients treated with simvastatin for 14 days [Plenge et al. 2002] . Our data confirms this, while TnT and CK 1 day after procedure was positively correlated with LDL reduction in the present study.
The ESTABLISH study showed a significant correlation between the change of LDL cholesterol and the change of plaque volume using intravascular ultrasound technique [Okazaki et al. 2004] . Though this trial needed 6 months to detect a significant difference, statin administration might have not only reduced plaque volume, but also improved endothelial function rapidly after ACS [Dupuis et al. 1999] . Plaque volume reduction and stabilization was related to the degree of LDL cholesterol reduction, and was considered to minimize procedural myocardial damage. These findings from the ESTABLISH study may help explain our data, as greater LDL reduction suggests that there was a greater excess of redundant serum LDL cholesterol, which may not have reduced accumulated plaque burden in coronary arteries during the short-term observation in our study. We believe that the redundant LDL cholesterol is a reflection of the amount of plaque accumulation that was markedly reduced with statin treatment, but caused elevation of myocardial markers soon after PCI in this study.
In the ARMYDA trial, pretreatment with atorvastatin resulted in significantly less procedural myocardial injury in elective coronary intervention [Pasceri et al. 2004] . While PCI were performed in an urgent fashion, our present study supports the importance of statin administration prior to PCI to reduce the procedural injury that might be associated with increased mortality [Ioannidis et al. 2003 ].
The precise underlying mechanism of inhibition of elevated myocardial enzymes and inflammatory markers by statins is not clearly defined, yet is considered to be the action by reducing inflammation, improving vascular endothelial functions, inhibiting thrombosis, and remodeling of plaque composition in the diseased vessel, namely the pleiotropic effects of statins [Okazaki et al. 2004; Jialal et al. 2001; Dupuis et al. 1999; Notarbartolo et al. 1995] . These favorable statin effects were observed in patients with average cholesterol levels and as well as patients with low LDL cholesterol levels [Hara et al. 2007; Ridker et al. 1998 ]. The benefits of aggressive statin treatment to patients with ACS have been demonstrated by the MIRACLE and PROVE-IT trials, and these trials established the superiority of high-dose atorvastatin administration. Although we were not able to use 80 mg of atorvastatin because of dosage restriction in Japan, results from our study using preprocedural 20 mg administration of atorvastatin are in concordance with results of these mega trials.
Study limitations
This was a prospective, randomized, multicenter designed study with a limited number of patients, and there was no long-term clinical follow-up data. However, the results of this study may give emphasis to the favorable effects of aggressive preprocedural statins on reducing myocardial injury after PCI to Japanese patients who suffered from non-ST elevation ACS. Long-term clinical follow-up with larger patient sample are needed to further assess the results from this study.
Conclusion
Aggressive statin usage before PCI to patients with non-ST elevation ACS is favorable to reduce myocardial damage after procedure. Changes in lipid profile as well as the degree of dyslipidemia at the periprocedural period may influence the extent of damage to myocardium. These findings support the accumulated evidence abroad, and have been confirmed within the Japanese population.
